Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chromocell Makes Chromovert Technology and Novel Compounds Available to Support COVID-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Maxim Group","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Chromocell Therapeutics Announce IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Benuvia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Chromocell Corporation

    Menu

    Chromocell Corporation

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Chromocell Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

              Details:

              The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.

              Lead Product(s): Diclofenac

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Benuvia Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership February 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Chromocell Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

              Details:

              Chromocell intends to use the net proceeds from the proposed offering to support the development of CC8464, which is being evaluated for treating eye pain.

              Lead Product(s): CC8464

              Therapeutic Area: Ophthalmology Product Name: CC8464

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Alliance Global Partners

              Deal Size: $6.6 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 21, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Chromocell Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

              Details:

              Chromocell intends to use the net proceeds from the proposed offering to support the development of CC8464, which is being evaluated for treating eye pain.

              Lead Product(s): CC8464

              Therapeutic Area: Ophthalmology Product Name: CC8464

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Alliance Global Partners

              Deal Size: $6.6 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Chromocell Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chromocell Therapeutics Announce IPO

              Details:

              The net proceeds will be used to fund company's continued research and product development of CC8464, an oral, potent, highly selective, peripherally-restricted inhibitor for the treatment of Erythromelalgia.

              Lead Product(s): CC8464

              Therapeutic Area: Neurology Product Name: CC8464

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Maxim Group

              Deal Size: $0.4 million Upfront Cash: Undisclosed

              Deal Type: Public Offering May 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Chromocell Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chromocell Makes Chromovert Technology and Novel Compounds Available to Support COVID-19 Research

              Details:

              Chromovert has been successfully used to identify a novel, non-addictive pain blocker that is in clinical development. The company is now making its technology available to the scientific community.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY